
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics is experiencing a notable increase in operating expenses, with FY25 expenses rising by 36% to $468 million compared to FY24, reflecting the company's investment in its therapeutic development pipeline and operational growth. The positive clinical outcomes associated with its lead candidate, z-rostudirsen, including significant improvements in dystrophin expression and cardiopulmonary function, underscore the therapeutic potential and market viability of Dyne’s FORCE platform and its promising pipeline. Moreover, the expected positive readout of a competitor's Phase III trial provides a potential catalyst for Dyne, enhancing the projection for substantial upside movement in the company's shares.
Bears say
Dyne Therapeutics Inc has reported a significant net loss of $446 million for the year, leading to an earnings per share (EPS) of ($3.47), which reflects a deterioration compared to the prior year's loss and EPS figures. Key downside risks include potential failures in clinical trials, particularly the DYNE-101 P1/2 ACHIEVE study, and various delays associated with regulatory pathways that could hinder market entry and overall development of the company’s therapeutics. Furthermore, the company has been trading at a discount relative to its peers, raising concerns regarding its DM1 program timeline and the uncertain outcomes of ongoing clinical studies, which could lead to further downward pressure on the stock.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares